上海医药(601607.SH)：西格列汀二甲双胍缓释片获得批准生产

智通财经02-04

智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)的西格列汀二甲双胍缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2026S00307)，该药品获得批准生产。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。该药品最早由Merck Sharp&Dohme公司开发，于2012年在美国...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608935442?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-04 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608935442","market":"sh","top_or_hot":-1,"title":"上海医药(601607.SH)：西格列汀二甲双胍缓释片获得批准生产","media":"智通财经","content":"<div>\n<p>智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)的西格列汀二甲双胍缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2026S00307)，该药品获得批准生产。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。该药品最早由Merck Sharp&Dohme公司开发，于2012年在美国...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401597.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海医药(601607.SH)：西格列汀二甲双胍缓释片获得批准生产</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海医药(601607.SH)：西格列汀二甲双胍缓释片获得批准生产\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-04 17:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1401597.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)的西格列汀二甲双胍缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2026S00307)，该药品获得批准生产。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。该药品最早由Merck Sharp&Dohme公司开发，于2012年在美国...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1401597.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1197","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1401597.html","article_id":"2608935442","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608935442","pubTimestamp":1770197682,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)的西格列汀二甲双胍缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2026S00307)，该药品获得批准生产。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。该药品最早由Merck Sharp&Dohme公司开发，于2012年在美国上市。2024年6月常州制药厂就该药品向国家药监局提出注册上市申请，并获受理。截至本公告日，公司针对该药品已投入研发费用约人民币849万元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK1197":"保健护理产品经销商","BK0020":"浦东新区","BK0184":"上海国资改革","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","BK0012":"证金概念","02607":"上海医药","BK0196":"行业龙头","BK0175":"白马股","BK0097":"医药电商","BK0187":"一线龙头","BK0028":"国家队","BK0099":"上海本地重组"},"translate_title":"Shanghai Pharmaceuticals (601607. SH): Sitagliptin metformin sustained-release tablets approved for production","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1.5,"02607":1.5},"content_text":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)的西格列汀二甲双胍缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2026S00307)，该药品获得批准生产。西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双胍缓释片联合治疗的成人2型糖尿病患者。该药品最早由Merck Sharp&Dohme公司开发，于2012年在美国上市。2024年6月常州制药厂就该药品向国家药监局提出注册上市申请，并获受理。截至本公告日，公司针对该药品已投入研发费用约人民币849万元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608935442","isCrawlerRequest":true}